RE: Stuff17 Jul 2019 18:09
Some info for the markets to wake up too.
Once the filed licence gets the approval, production will commence. This product is massive, can't see M/C at this level for much longer. Only 81.56M shares in issue. Even at 30p that's only a M/C of @ £24M. Plenty cash in the bank too.
Letter from the CEO:
With the successful conclusion of last year's acquisition of IVIX LLC ("IVIX") and the re-admission of the enlarged group on Euronext Dublin and the London Stock Exchange, the foundation was put in place for establishing Ovoca as a recognized developer of novel therapeutics for women's health, especially in the area of sexual dysfunction. Our colleagues at IVIX continue to build out our successful BP101 program, which you will have seen in March 2019 comfortably exceeded the efficacy and safety hurdles in its Phase 3 trial in Russia. As a result, we are now preparing to file for the drug's marketing approval in its first country, the Russian Federation, and actively pursuing discussions with potential licensing partners to commercialize there.
Boris Reznik, chairman of Biorasi added: "We are very excited to begin this project with Ovoca/IVIX. Their BP-101 drug candidate has shown promising performance in clinical trials so far, and we believe there is high potential in bringing it over to the EU and US markets."